The objective ofthis study was to assess, in a developing country setting, the effect of dexamethasone therapy on bacterial meningitis outcomes. A prospective double blind placebo controlled trial was conducted in 89 children aged from 2 months to 12 years suffering from bacterial meningitis. Neurological, developmental, and hearing assessments were conducted at one, four, and 12 months after discharge. Forty eight patients received dexamethasone and 41 placebo. Initial antimicrobial drugs used were ampicillin and chloramphenicol. For all patients at the time of admission the mean duration of illness was 5.7 days; 47% had had seizures and 56% had impaired consciousness. Seventeen of 89 (19%) patients died. The mortality for the dexamethasone group was 25% as compared with 12% in the group receiving placebo. Presentation to the hospital after four days of symptoms and with impaired conscious state were independent predictors of death. Of the dexamethasone group survivors, 26.5% had neurological sequelae and 42.3% had hearing impairment, whereas in the placebo group it was 24% and 30% respectively. Altered state of consciousness was a predictor of neurological sequelae. The presence of neurological sequelae and high cerebrospinal fluid protein independently predicted hearing loss. No beneficial effect of dexamethasone was observed on morbidity or mortality of this group of patients with bacterial meningitis. Dexamethasone is therefore not useful in developing countries as adjunctive treatment in patients seriously ill with bacterial meningitis, who present late for treatment and have been partially treated. (Arch Dis Child 1996;75:482-488) 
blind placebo controlled trial was conducted in 89 children aged from 2 months to 12 years suffering from bacterial meningitis. Neurological, developmental, and hearing assessments were conducted at one, four, and 12 months after discharge. Forty eight patients received dexamethasone and 41 placebo. Initial antimicrobial drugs used were ampicillin and chloramphenicol. For all patients at the time of admission the mean duration of illness was 5.7 days; 47% had had seizures and 56% had impaired consciousness. Seventeen of 89 (19%) patients died. The mortality for the dexamethasone group was 25% as compared with 12% in the group receiving placebo. Presentation to the hospital after four days of symptoms and with impaired conscious state were independent predictors of death. Of the dexamethasone group survivors, 26.5% had neurological sequelae and 42.3% had hearing impairment, whereas in the placebo group it was 24% and 30% respectively. Altered state of consciousness was a predictor of neurological sequelae. The presence of neurological sequelae and high cerebrospinal fluid protein independently predicted hearing loss. No beneficial effect of dexamethasone was observed on morbidity or mortality of this group of patients with bacterial meningitis. Dexamethasone is therefore not useful in developing countries as adjunctive treatment in patients seriously ill with bacterial meningitis, who present late for treatment and have been partially treated. Bacterial meningitis is an important cause of morbidity and mortality world wide.1`5 Despite availability of rapid accurate diagnostic techniques, improved antimicrobial treatment, and supportive care, 14-31% of children with bacterial meningitis develop neurological sequelae.' [6] [7] [8] [9] Haemophilus influenzae b vaccine is now routinely administered to children under the age of 2 years to prevent invasive disease, including meningitis. Since the cost of routine immunisation in developing countries is unfortunately likely to be prohibitive, the search for alternative strategies to prevent the neurological sequelae caused by bacterial meningitis remains a priority.
Since steroids may reduce central nervous system inflammation, the safety and efficacy of dexamethasone in the prevention of central nervous system abnormalities after bacterial meningitis have been intensively investigated.""'6 Fewer neurological sequelae occurred in children who were treated with dexamethasone in addition to standard antimicrobial therapy (mostly cefuroxime, cefotaxime, and ceftriaxone), but differences were not statistically significant in two of the six clinical trials." '5 physical examination was carried out, which included neurological and otoscopic examination. All children suspected of having meningitis underwent the following diagnostic procedures: a lumbar puncture; a set of blood cultures; urine latex agglutination and culture; a chest radiograph; serum electrolytes, serum and urine osmolality, blood glucose; blood urea nitrogen; serum creatinine; erythrocyte sedimentation rate; complete peripheral blood count; and a stool examination for occult blood (side effect of dexamethasone) (Hematest tablets). Cerebrospinal fluid (CSF) was evaluated as follows: cell count with differential, protein, glucose, Gram and Ziehl-Neelsen (acid fast) stain of sediment centrifuged for five minutes at 1500 rpm, latex agglutination to detect Haemophilus influenzae type b, Streptococcus pneumoniae, Neisseria meningitidis serotypes A, B, C, Y, Streptococcus agalactiae, and Escherichia coli k using the Wellcogen bacterial antigen kit (1) and routine culture.
DEFINITION OF BACTERIAL MENINGITIS
The preliminary diagnosis of bacterial meningitis was based on any one of the following: (i) presence of bacteria on CSF Gram stain; (ii) a positive CSF latex agglutination test; or (iii) at least two or three of the following CSF abnormalities: leucocytes >1000x106 cells/l, predominantly polymorphonuclear, protein >1 g/l, glucose <1.66 mmol/l, or <50% of serum glucose. Isolation of an identified nonmycobacterial pathogen obtained by either culture of two or three drops of CSF sediment on blood agar, chocolate agar, McConkey plates and thioglycolate broth, or routine culture media or by blood or CSF culture in brain-heart infusion broth (Roche, Switzerland) provided bacteriological confirmation of the diagnosis of meningitis. In vitro susceptibilities of all isolates to ampicillin, chloramphenicol, and cefotaxime were tested using Kirby-Bauer disk diffusion.
The diagnosis of bacterial meningitis in this study excluded patients who had had an initial diagnosis of bacterial meningitis but were diagnosed with tuberculous meningitis (based on the following: absence of bacteria in routine culture or detected by latex agglutination, a positive Mantoux test, sedimentation rates greater than 50 mm per hour, abnormalities on chest radiographs consistent with tuberculosis, and contact with a person with tuberculosis) or aseptic meningitis (based on the following in initial and subsequent CSF samples: absence of bacteria in routine culture or detected by latex agglutination, <100Ox106 cells/l (80% or more lymphocytes), protein <1 g/l, glucose >1.66 mmol/l, or >50% of serum glucose) or had obvious viral infection, for example herpes, mumps, measles, chickenpox, etc.
TREATMENT PROTOCOL All children who fulfilled the above initial criteria for bacterial meningitis were treated with ampicillin (300 mg/kg per day in four divided doses) and chloramphenicol (100 mg/kg per day in four divided doses).' Patients were assigned to receive either intravenous dexamethasone (0.6 mg/kg per day in four divided doses)'" or an equal volume of placebo (two thirds normal saline) using an unconstrained computer generated list of random treatment assignments. The first dose of dexamethasone or placebo was administered 10-15 minutes before administration of antibiotic and was continued for four days. The identical appearing solutions of dexamethasone and placebo were prepared by the study pharmacist to ensure that neither patient nor investigator was aware of assignment to the drug. The pharmacist in Japan kept the details of the randomisation, and the code was broken after completion of the study.
All participants had a second lumbar puncture approximately 48 hours after initiation of therapy to determine whether CSF abnormalities were improving or worsening and to attempt continued isolation of bacteria. Patients who deteriorated clinically (defined as deteriorating consciousness, no improvement in meningeal irritation (Kernig and Brudinski signs), worsening of presenting symptoms, persistent vomiting or persistence of fever with a temperature higher than 38.9'C) in the first 48-72 hours or whose 48 hour CSF formula was unchanged were switched to intravenous cefotaxime (200 mg/kg per day in four divided doses).9 Antibiotic treatment, with or without dexamethasone, was continued for a minimum of 10 days. The treating physician made the decision to stop treatment after 10 or more days of antibiotics9 based on each patient's clinical course. Supportive care in an intensive care unit was provided as clinically indicated. A lumbar puncture was performed before discharge to ensure that the CSF was sterile.
EVALUATION OF TREATMENT: DEFINITIONS OF OUTCOME MEASURES
Patients were examined clinically at least twice daily during their hospital stay and examined for long term sequelae one year after admission. The following outcome parameters were evaluated: (i) response to treatment, (ii) complications of treatment (untoward events and mortality), (iii) neurological sequelae (neurological, audiological, and developmental assessments).
Response to treatment
Patients who responded to treatment fulfilled all of the following criteria: improvements in presenting signs and symptoms, particularly improved level of consciousness and absence of meningeal irritation, normalisation of CSF cell count, glucose, protein, and sterility of CSF in subsequent culture.
Complications of treatment
The presence of all untoward events, including death, and their possible relation to administration of the study drugs was assessed daily. These events included secondary fever (defined as recurrence of temperatures higher than 37.8°C after 24 hours or more and evidence of gastrointestinal bleeding assessed by occult blood testing at least three times per week).
Neurological sequelae State of consciousness was evaluated daily and classified as alert, drowsy (defined as arousal by mild external stimulation, lapsed into sleep-like state when the stimulus was removed'9) or comatose (defined as a state of altered consciousness in which patient is unresponsive to any environmental stimulus '9) . Other neurological sequelae such as subdural effusion, dilated ventricles, cerebral infarction and atrophy, and brain abscess were initially detected by ultrasound in patients with an open fontanelle, later confirmed by computed tomography. In older children computed tomography was used to confirm these complications. Ventriculitis was confirmed by ventricular tap and CSF examination. Inappropriate secretion of antidiuretic hormone was diagnosed by absence of volume depletion, decreased serum osmolality and hyponatraemia, urine osmolality greater than appropriate for concomitant serum osmolality and normal renal, adrenal, and thyroid function.The presence of cranial nerve palsies and optic atrophy was detected on daily physical examination.
Children who survived to discharge had audiological, neurological, and developmental assessments at one, four, and 12 (27) 8 (23) tistically significant. Although an overall (9) 2 (6) mortality of 19% is higher than reported in (12) 8 (23) most US and European studies, mortality in (6) 3 (9) studies from Pakistan range between 18 and (6) 1 (3) 29%. '7 " In our study, factors relating to late 26 32,125(3) presentation-duration of illness more than four days and impaired consciousness at (39) 11 (34) admission-were the only significant predic- (39) 4 (16) did not enrol sufficient patients to evaluate the efficacy of dexamethasone for prevention of and audiological and mortality caused by bacterial meningitis. In our uelae in children with bacterial study, mortality was higher in children treated study had sufficient statistical with dexamethasone, although the difference a difference of 25% or more in in mortality between the groups did not uelae and a 50% reduction in achieve statistical significance. Our overall results are similar to those obtained in a study of children with bacterial meningitis from Mozambique.'6 Although Ciana et al 16 observed a reduction in early mortality from 22% in children treated with ampicillin and chloramphenicol to 3% in children treated with dexamethasone in combination with ampicillin and chloramphenicol (p=0.03), overall mortality was similar in the two groups (24% in the dexamethasone treated group, 33% in the antibiotics only group). Second, we did not prospectively record the severity of the illness in patients presenting with bacterial meningitis (such as by using the Glasgow coma scale). Thus we were not able to investigate the relationship between severity of illness and outcome. Third, no organism was isolated from the CSF of more than 50% of our patients. Many patients had received incomplete oral courses of antibiotics before presentation at our hospital. These partially treated patients may have had undetected organisms resistant to ampicillin and chloramphenicol. We were not able to evaluate the impact of partial treatment and undetected resistance on the outcome. Fourth, although our hospital has a 10 bed intensive care unit with facilities for artificial ventilation, access is limited by bed availability. We were not able to evaluate the impact of bed availability in the intensive care unit on the outcome because this information was not recorded. Fifth, we were unable to carry out pneumatic otoscopy or tympanography and thus were unable to assess the middle ear function at the time of admission. Sixth, the possibility of the occasional misdiagnosis of aseptic meningitis as bacterial meningitis cannot be ruled out.
How then should children in developing countries who present with bacterial meningitis be treated? Perhaps the most important conclusion of this study is that the emphasis must remain on either prevention or early diagnosis and referral, since factors associated with delay predict increased mortality and neurological and audiological sequelae. It is possible that dexamethasone is beneficial in selected patients who present early in the course of the illness, but a recommendation to administer adjunct dexamethasone for treatment of bacterial meningitis in children in developing countries appears to be premature at this time. This study was conducted in the referral and clinical situation that currently exists in many poor countries. It accurately represents the actual environment.
When resources are limited in both developed and developing countries, effective strategies to prevent poor outcomes in children with bacterial meningitis should probably focus on the following: (i) immunisation against bacteria causing meningitis (H influenzae) despite logistical challenges and costs associated with vaccine administration; (ii) rapid diagnosis and institution of antibiotic treatment despite limited primary health care facilities and laboratories8 28; (iii) continued evaluation of appropriate antibiotic treatment as resistance of common pathogens to ampicillin and chloramphenicol becomes more widespread. Currently, chloramphenicol is effective against most strains of penicillin resistant S pneumoniae and P-lactamase positive strains of H influenzae,l although the clinical failure of chloramphenicol for treatment of penicillin resistant S pneumoniae strains has been reported."3 In Pakistan, a third generation cephalosporin costs approximately three times as much as the ampicillin/chloramphenicol combination. This difference prohibits use of third generation cephalosporin as the drug of choice for bacterial meningitis. The costs of prevention and/or treatment of bacterial meningitis in children remain substantial, but the cost of adjunct dexamethasone in developing countries such as Pakistan does not appear to be justified at this time.
